Valeant To 'Improve' Terms After Allergan Rejects $46B Bid
One day after Allergan Inc. rejected Valeant Pharmaceuticals International Inc.'s $46 billion takeover proposal, Valeant said it remained committed to sealing a deal and would beef up its offer after discussing...To view the full article, register now.
Already a subscriber? Click here to view full article